These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29293545)

  • 1. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study.
    Begg GA; Karim R; Oesterlein T; Graham LN; Hogarth AJ; Page SP; Pepper CB; Rhode K; Lip GYH; Holden AV; Plein S; Tayebjee MH
    PLoS One; 2018; 13(1):e0189936. PubMed ID: 29293545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation.
    Begg GA; Karim R; Oesterlein T; Graham LN; Hogarth AJ; Page SP; Pepper CB; Rhode K; Lip GYH; Holden AV; Plein S; Tayebjee MH
    Europace; 2017 Dec; 19(12):1944-1950. PubMed ID: 28339804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between left atrial low-voltage area, serum apoptosis, and fibrosis biomarkers and incidence of silent cerebral events after catheter ablation of atrial fibrillation.
    Müller P; Maier J; Dietrich JW; Barth S; Griese DP; Schiedat F; Szöllösi A; Halbfass P; Nentwich K; Roos M; Krug J; Schade A; Schmitt R; Mügge A; Deneke T
    J Interv Card Electrophysiol; 2015 Oct; 44(1):55-62. PubMed ID: 26048130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation.
    Begg GA; Swoboda PP; Karim R; Oesterlein T; Rhode K; Holden AV; Greenwood JP; Shantsila E; Lip GYH; Plein S; Tayebjee MH
    J Cardiovasc Magn Reson; 2020 Feb; 22(1):13. PubMed ID: 32036784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the extent of low-voltage zone on outcomes after voltage-based catheter ablation for persistent atrial fibrillation.
    Yamaguchi T; Tsuchiya T; Fukui A; Kawano Y; Otsubo T; Takahashi Y; Hirota K; Murotani K; Eshima K; Takahashi N
    J Cardiol; 2018 Nov; 72(5):427-433. PubMed ID: 29807864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Circulating Fibrocytes Is a Marker of Left Atrial Fibrosis and Recurrence of Persistent Atrial Fibrillation.
    Liu Y; Niu XH; Yin X; Liu YJ; Han C; Yang J; Huang X; Yu X; Gao L; Yang YZ; Xia YL; Li HH
    J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29535140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Voltage Mapping to Guide Whether to Perform Ablation of the Posterior Wall in Patients With Persistent Atrial Fibrillation.
    Cutler MJ; Johnson J; Abozguia K; Rowan S; Lewis W; Costantini O; Natale A; Ziv O
    J Cardiovasc Electrophysiol; 2016 Jan; 27(1):13-21. PubMed ID: 26515166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation.
    Ravassa S; Ballesteros G; López B; Ramos P; Bragard J; González A; Moreno MU; Querejeta R; Vives E; García-Bolao I; Díez J
    J Am Coll Cardiol; 2019 Apr; 73(12):1398-1410. PubMed ID: 30922470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum TGF-β1 level in atrial fibrosis and outcome after catheter ablation for paroxysmal atrial fibrillation.
    Tian Y; Wang Y; Chen W; Yin Y; Qin M
    Medicine (Baltimore); 2017 Dec; 96(51):e9210. PubMed ID: 29390467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
    Kornej J; Schmidl J; Ueberham L; John S; Daneschnejad S; Dinov B; Hindricks G; Adams V; Husser D; Bollmann A
    PLoS One; 2015; 10(4):e0123574. PubMed ID: 25875595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease.
    Wu XY; Li SN; Wen SN; Nie JG; Deng WN; Bai R; Liu N; Tang RB; Zhang T; Du X; Dong JZ; Ma CS
    Europace; 2015 Oct; 17(10):1541-7. PubMed ID: 25921557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-voltage areas detected by high-density electroanatomical mapping predict recurrence after ablation for paroxysmal atrial fibrillation.
    Vlachos K; Efremidis M; Letsas KP; Bazoukis G; Martin R; Kalafateli M; Lioni L; Georgopoulos S; Saplaouras A; Efremidis T; Liu T; Valkanas K; Karamichalakis N; Asvestas D; Sideris A
    J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1393-1402. PubMed ID: 28884923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Duration of the Amplified Sinus-P-Wave Identifies Presence of Left Atrial Low Voltage Substrate and Predicts Outcome After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation.
    Jadidi A; Müller-Edenborn B; Chen J; Keyl C; Weber R; Allgeier J; Moreno-Weidmann Z; Trenk D; Neumann FJ; Lehrmann H; Arentz T
    JACC Clin Electrophysiol; 2018 Apr; 4(4):531-543. PubMed ID: 30067494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation.
    Zhao F; Zhang S; Chen Y; Gu W; Ni B; Shao Y; Wu Y; Qin J
    BMC Cardiovasc Disord; 2014 Nov; 14():167. PubMed ID: 25422138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome.
    Richter B; Gwechenberger M; Socas A; Zorn G; Albinni S; Marx M; Wolf F; Bergler-Klein J; Loewe C; Bieglmayer C; Binder T; Wojta J; Gössinger HD
    Int J Cardiol; 2011 Oct; 152(2):231-6. PubMed ID: 20692054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation.
    Masuda M; Fujita M; Iida O; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Okuno S; Ohashi T; Tsuji A; Mano T
    Int J Cardiol; 2018 Apr; 257():97-101. PubMed ID: 29506746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation - the FIBRO-RISK study: Protocol for a non-randomized clinical trial.
    Korodi S; Toganel R; Benedek T; Hodas R; Chitu M; Ratiu M; Kovacs I; Mester A; Benedek I
    Medicine (Baltimore); 2019 Mar; 98(9):e14504. PubMed ID: 30817568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome after catheter ablation for atrial fibrillation.
    Ling LH; McLellan AJ; Taylor AJ; Iles LM; Ellims AH; Kumar S; Teh A; Lee G; Wong MC; Azzopardi S; Sellenger MA; Morton JB; Kalman JM; Kistler PM
    Heart Rhythm; 2014 Sep; 11(9):1551-9. PubMed ID: 24931636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic atrial fibrillation is a biatrial arrhythmia: data from catheter ablation of chronic atrial fibrillation aiming arrhythmia termination using a sequential ablation approach.
    Rostock T; Steven D; Hoffmann B; Servatius H; Drewitz I; Sydow K; Müllerleile K; Ventura R; Wegscheider K; Meinertz T; Willems S
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):344-53. PubMed ID: 19808429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiofrequency Ablation of Persistent Atrial Fibrillation: Diagnosis-to-Ablation Time, Markers of Pathways of Atrial Remodeling, and Outcomes.
    Hussein AA; Saliba WI; Barakat A; Bassiouny M; Chamsi-Pasha M; Al-Bawardy R; Hakim A; Tarakji K; Baranowski B; Cantillon D; Dresing T; Tchou P; Martin DO; Varma N; Bhargava M; Callahan T; Niebauer M; Kanj M; Chung M; Natale A; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e003669. PubMed ID: 26763227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.